Fig. 1: The relative antibody and cellular immune responses following bivalent vaccination in patients with CLL.

a Spike-specific antibody titre in participants with a positive antibody response following bivalent vaccine dose (n = 41) compared to controls (n = 70) (p = 0.188; Mann–Whitney U test). Participants with evidence of natural infection were excluded. The cut-off for a positive response is indicated by the dotted line (Geometric mean and 95% CI shown). b Infographic to show percentage with detectable antibody response by disease group characteristic. Those grouped in BTKi/BCL2i represent all donors who have received or continue to take either line of treatment, since January 2021 (n = 23). c Ancestral B.1 (n = 34) and BA.1 (n = 33) specific antibody responses before and after bivalent vaccine dose in infection naïve participants (fold change shown). d ND50 neutralising antibody titres against viral pseudotypes bearing ancestral or BA.1 Omicron spike glycoproteins pre and post-bivalent vaccine dose amongst 37 infection naïve participants (fold change, GM and 95% CI shown; p < 0.0001 Kruskal–Wallis with BA.1 comparison by paired multiple comparison test p = 0.059). e ND50 neutralising antibody titres against viral pseudotypes for the latest variants of concern (BA.4/5, BQ1.1 and XBB) are shown in 10 infection naïve donors (Geometric mean and 95% CI shown). f IFN-gamma ELISpot assay before and after bivalent vaccine dose in infection-naïve CLL. patients following peptide stimulation with either ancestral (p = 0.01) or BA.1 Omicron peptide pool (p = < 0.0001) (Friedman test Median and IQR shown) (n = 9).